In the study, alteration of vitamin D dosage was not permitted except for the case in which serum calcium could not be managed by calcium carbonate adjustment alone.
Results. After 12 weeks of cinacalcet treatment, FGF23 levels decreased significantly concomitantly with a significant reduction in intact parathyroid hormone (PTH) levels. These responses were sustained >52 weeks. In multivariate regression analyses, changes from baseline in serum FGF23 were associated with changes in serum calcium and phosphorus but not with intact PTH at each time point of measurements (Week-12, Week-24 and Week-52). Baseline FGF23 was not associated with the likelihood of achieving an intact PTH <180 pg/mL at the study end.
Conclusions. Cinacalcet lowers serum FGF23 in haemodialysis patients with SHPT independently of the effects of active vitamin D. Pretreatment FGF23 cannot predict treatment response to cinacalcet in this setting. The precise mechanism of FGF23 reduction by cinacalcet and its clinical impact on outcomes in patients remain to be investigated.
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Introduction
Secondary hyperparathyroidism (SHPT) is a common complication among long-term dialysis patients [1, 2] . It is characterized by increased synthesis and secretion of parathyroid hormone (PTH), mainly due to disturbances of calcium, phosphate and vitamin D metabolism. In addition, recent data suggest that fibroblast growth factor 23 (FGF23), a bone-derived phosphaturic hormone, plays a central role in the pathogenesis of SHPT [3, 4] . FGF23 is primarily secreted by osteocytes and has several endocrine effects on phosphorus and vitamin D metabolism [5] . FGF23 induces urinary phosphate excretion by decreasing expression of sodium-phosphate co-transporters and suppresses renal production of 1,25-dihydroxyvitamin D by inhibiting 1a-hydroxylase and stimulating 24-hydroxylase [6, 7] . In patients with chronic kidney disease (CKD), serum levels of FGF23 are progressively increased as kidney function declines, possibly to maintain neutral phosphorus balance [8, 9] . This compensation by increased FGF23, however, results in suppression of renal 1,25(OH) 2 D production and thereby triggers the early development of SHPT [3, 4] . FGF23 also acts on the parathyroid to suppress PTH secretion [10] , but this effect is disturbed in patients with SHPT owing to decreased expression of FGF23's receptor complex, Klotho-FGF receptor 1 [11, 12] .
Recently, several clinical studies of CKD patients reported that high levels of FGF23 are associated with progression of CKD [13] , vascular calcification [14] , left ventricular hypertrophy [15] and increased mortality [16] . It is also known that pretreatment FGF23 predicts parathyroid resistance to active vitamin D therapy [17] and future development of refractory SHPT [18] . Given these data suggesting the potential of FGF23 as a novel biomarker, it is important to know how these levels can be altered by treatment for mineral and bone disorders. Although their clinical significance remains to be elucidated, recent studies show that FGF23 levels can be elevated by injectable active vitamin D treatment [19] and lowered by oral phosphate binders [20, 21] .
Cinacalcet hydrochloride is a calcimimetic agent that acts as an allosteric modulator of the calcium-sensing receptor (CaSR). Results from several clinical trials indicate that treatment with cinacalcet effectively lowers PTH levels and concurrently lowers serum calcium and phosphorus in patients with moderate-to-severe SHPT [22] [23] [24] [25] . However, the effect of cinacalcet on serum FGF23 levels has not been sufficiently investigated. It is also unclear whether pretreatment FGF23 predicts response to cinacalcet therapy in the same way as active vitamin D treatment-bound [17, 18] . To examine these issues, we measured serum FGF23 levels of prospectively collected samples in our previous clinical trial that examined the effect of cinacalcet on parathyroid hyperplasia [25] .
Materials and methods

Study design
This was a secondary analysis of a 52-week, multicentre, open-label single-arm trial that examined the effect of cinacalcet on SHPT in haemodialysis patients with parathyroid hyperplasia. Study procedures have been described elsewhere [25] . In brief, patients were considered for the study if they were 18 years of age or older, had required maintenance dialysis for at least 16 weeks, had serum intact PTH >300 pg/mL and had serum calcium >9.0 mg/dL. The study period consisted of a 30-day screening period, a 12-week dose-titration phase, a 26-week maintenance phase and a 14-week efficacy-assessment phase. Cinacalcet hydrochloride (RegparaÒ; Kyowa Hakko Kirin, Co., Ltd, Tokyo, Japan) was initiated at 25 mg daily and increased sequentially (25, 50, 75 and 100 mg) in an attempt to achieve the target ranges specified in the Japanese Society for Dialysis Therapy guideline (calcium, 8.4-10.0 mg/dL; phosphorus, 3.5-6.0 mg/dL; intact PTH, 60-180 pg/mL) [26] . The dose of vitamin D sterols was increased only if the serum calcium remained <8.4 mg/dL or if hypocalcaemic symptoms persisted despite an increase in the dose of calcium carbonate to 3000 mg daily. Reductions in the doses of vitamin D sterols were permitted in cases in which the serum calcium was >10.0 mg/dL. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the institutional review board of Kobe University School of Medicine, which waived the need for additional written informed consent for this secondary analysis.
Measurements
Serum samples were collected prospectively for measuring FGF23 levels at baseline and at Week-12, Week-24 and Week-52 and transferred frozen to the Kobe University School of Medicine. Serum FGF23 levels were determined using a sandwich ELISA kit (Kainos Laboratories, Tokyo, Japan) that exclusively detects the full-length FGF23 peptide. Serum intact PTH, calcium and phosphorus were measured at local laboratories. Serumintact PTH levels were determined using an electrochemiluminescence immunoassay (Elecsys PTH; Roche Diagnostics, Mannheim, Germany). Serum calcium levels were corrected for albumin concentration using Payne's formula [27] .
Statistical analysis
Results are reported as mean AE SD for normally distributed variables and median [interquartile range (IQR)] for variables with skewed distributions. Correlations between baseline laboratory values were examined by linear regression analysis. Changes in serum calcium, phosphorus, intact PTH and FGF23 from baseline were analysed using repeated measures analysis of variance (ANOVA) followed by Bonferroni post hoc test. Univariate and multivariate linear regression analyses were used to assess the association between changes in FGF23 levels from baseline and that of each biochemical parameter at each time point (Week-12, Week-24 and Week-52). We also examined these associations, adjusting for changes from baseline in the doses of injectable active vitamin D. Because serum-intact PTH and FGF23 levels were not normally distributed, we analysed log-transformed values in the ANOVA and linear regression analyses. Logistic regression analysis was used to examine whether pretreatment FGF23 levels predict the likelihood of achieving an intact PTH <180 pg/mL. We also compared baseline FGF23 levels of patients who achieved an intact PTH <180 pg/mL at the study end and those who did not using Wilcoxon rank-sum test. A 10-lg dose of maxacalcitol was considered to be equal to 1.5 lg of calcitriol, and all results for injectable active vitamin D dosages are presented as calcitriol equivalents. P < 0.05 was considered statistically significant. All analyses were performed using Dr SPSS II for Windows, version 11.01 J (SPSS Japan, Tokyo, Japan).
Results
Study population and baseline results
Of the 81 patients enrolled in the original trial, 55 patients completed the 52-week trial and had available serum samples for the analysis. Table 1 shows the baseline characteristics of the study subjects. Overall, the demographic and mineral metabolic parameters of the study subjects were comparable to that of the general participants of the trial. According to the inclusion criteria, all patients had intact PTH levels >300 pg/mL (median 499 pg/mL, IQR 360-699 pg/mL). Approximately two-thirds of patients were receiving injectable active vitamin D, and the mean AE SD dose was 2.32 AE 1.20 lg/week of calcitriol equivalents. At baseline, serum FGF23 levels were markedly elevated (median 14 750 pg/mL, IQR 3055-23 991 pg/mL), as reported previously [11, 17, 18] . These levels positively correlated with serum phosphorus (r ¼ 0.57, P < 0.001), calcium (r ¼ 0.32, P ¼ 0.02) and intact PTH levels (r ¼ 0.48, P < 0.001).
Effect of cinacalcet on FGF23, intact PTH and mineral metabolism
After 12 weeks of cinacalcet treatment, FGF23 levels decreased substantially from 14 750 pg/mL (IQR, 3055-23 991 pg/mL [37] ) at baseline to 5121 pg/mL (IQR, 1869-18 315 pg/mL) (P ¼ 0.002), concomitantly with a significant reduction in intact PTH levels from 499 pg/mL (IQR, 360-699 pg/mL) at baseline to 220 pg/mL (IQR, 126-383 pg/mL) (P < 0.001). These levels remained largely stable through Week-52 ( Figure 1A and B) . Serum calcium levels declined significantly after 12 weeks of treatment and remained stable throughout the study ( Figure 1C) . Serum phosphorus levels also declined significantly after 12 weeks of treatment but gradually increased thereafter ( Figure 1D ). The use and dose of intravenous active vitamin D remained largely unchanged during the study period according to the study protocol ( Table 2 ). Exclusion of patients in whom the use or dose of intravenous active vitamin D was changed during treatment did not alter the effects of cinacalcet on serum FGF23 from 6392 pg/mL (IQR, 2547-21 581 pg/mL) at baseline to 5011 pg/mL (IQR, 1011-15 042 pg/mL) at the study end, P ¼ 0.02.
Associations between FGF23 reduction and mineral metabolism alterations
To determine factors that were responsible for the changes in FGF23, we examined associations between changes in FGF23 levels and biochemical response to cinacalcet by univariate and multivariate linear regression models. At each time point of measurement, percent changes in serum calcium and phosphorus, but not intact PTH, were independent determinants of percent changes in log FGF23 (Table 3) . These results were unaltered by further adjustment for absolute changes in the dose of intravenous active vitamin D.
Pretreatment FGF23 and achievement of the target intact PTH
Forty-six percent of patients (25 of 55) achieved an intact PTH <180 pg/mL at the end of study. Logistic regression analysis showed that baseline levels of FGF23 did not predict the likelihood of achieving an intact PTH <180 pg/mL [odd ratio, 0.96 (95% confidence interval, 0.92-1.00), P ¼ 0.06]. There were also no significant changes in baseline FGF23 levels between those who achieved the target and those who did not [6392 (IQR, 3170-18 087) versus 19 491 (IQR, 3010-30 754), P ¼ 0.1]. Also, no significant associations were found between pretreatment log FGF23 and percent change in log-intact PTH at each time point.
Discussion
In this secondary analysis of a multicentre single-arm clinical trial, treatment with cinacalcet hydrochloride substantially lowered serum FGF23 levels concomitantly with reductions in serum calcium, phosphorus and intact PTH levels. The observed reductions in FGF23 were associated with reductions in serum calcium and phosphorus during the treatment period but not with suppression of PTH levels. This study also demonstrated that, in contrast to the results of previous studies of active vitamin D therapy [17, 18] , pretreatment FGF23 levels could not be a predictor of treatment response to cinacalcet in patients with SHPT. Our results should be considered in the context of a previous study by Wetmore et al. [28] , who showed that a treatment strategy of cinacalcet plus low-dose calcitriol analogues results in a greater decrease in FGF23 levels compared with treatment with titrated doses of active vitamin D. Although both studies suggest that the addition of cinacalcet to conventional treatment results in a significant reduction in FGF23 levels, there is an important difference between the study protocols of Wetmore et al. and ours. The study by Wetmore et al. [24] built on the ACHIEVE protocol, in which participants in the cinacalcet arm were withdrawn from their active vitamin D and thereafter treated with fixed low-dose active vitamin D. Because active vitamin D strongly stimulates FGF23 production in osteoblasts [29] and also increases serum FGF23 levels in haemodialysis patients [19] , the reduction in serum FGF23 in the cinacalcet group may in part be attributed to the lower exposure to active vitamin D. By contrast, our study protocol did not permit alteration of vitamin D dosage except for the case in which serum calcium could not be managed by calcium carbonate adjustment. This resulted in a relatively constant dosage of active vitamin D during the study period, allowing us to isolate the effects of cinacalcet on serum FGF23 from those of active vitamin D. Furthermore, we also observed a significant decrease in FGF23 levels in the analysis that was restricted to patients in whom the use or dose of intravenous active vitamin D was actually unchanged during treatment. Our results, therefore, support the possibility that cinacalcet treatment per se leads to a reduction in FGF23 levels, although this effect might be mediated by changes in other mineral metabolic parameters during the treatment.
The mechanisms responsible for the reduction in FGF23 levels during treatment with cinacalcet are uncertain, but several possibilities exist. In this study, we found that percent changes in serum calcium and phosphorus were associated with percent changes in log FGF23, both in univariate and multivariate regression models. One of the hypotheses derived from these results is that alterations in serum calcium mediated the effect of cinacalcet on FGF23 reduction. Although bone cells are known to express the CaSR [30] , it is still unclear whether extracellular calcium or its sensing mechanism plays a role in the regulation of FGF23 secretion. There are several clinical [31] and in vivo data [32] linking serum calcium to FGF23 levels, whereas an in vitro study suggests that changes in extracellular calcium do not directly stimulate FGF23 promoter activity in osteoblasts [29] . Whether the decreased serum calcium or increased sensitivity of the CaSR in bone cells induced by cinacalcet contributes to the reduction in FGF23 or it only reflects the biological effects of cinacalcet on mineral metabolism requires further investigations.
Another possibility is that alterations in phosphorus metabolism were a potential mediator of the FGF23 reduction by cinacalcet therapy. Although the sensing mechanism of phosphorus and its role in the regulation of FGF23 secretion remains unclear [33] , several lines of evidence indicate that reducing phosphorus retention, either by dietary phosphorus restriction [34, 35] or therapy with phosphate binders [20, 21] , lowers serum FGF23. Because cinacalcet treatment not only suppresses PTH but also reduces serum phosphorus [22] [23] [24] [25] , it is possible that the decreased serum phosphorus by cinacalcet caused the reduction in FGF23 levels in our study. It should, however, be noted that a recent animal study reported a significant reduction in FGF23 levels in CKD rats treated with cinacalcet, which occurred despite a marked increase in serum phosphorus [36] . Although the precise mechanisms of these discrepant findings are unclear, it is suggested that there are several other pathways that are involved in the FGF23 reduction induced by cinacalcet treatment.
In this regard, a recent experimental study by LaviMoshayoff et al. [37] is worthy of consideration. The investigators showed that PTH acts directly on bone cells to increase FGF23 secretion and messenger RNA expression both in vivo and in vitro, completing a PTH-FGF23 endocrinologic feedback axis. These findings are in line with clinical observation that severe SHPT is associated with FGF23 overproduction [17, 18] and surgical parathyroidectomy for severe SHPT results in significant reductions in serum FGF23 [38] . Therefore, although our multiple regression analysis disclosed that the reductions in FGF23 by cinacalcet were not independently associated with suppression of PTH levels, the possibility that the cinacalcetinduced reduction in serum PTH or its subsequent effects on bone metabolism contributes to the reduction in FGF23 should still be considered.
Although the precise mechanism by which cinacalcet therapy reduces serum FGF23 is unclear, this effect is of particular interest in terms of its clinical impact on patient outcomes. A post hoc analysis of randomized controlled trials showed that cinacalcet treatment resulted in a significant reduction in cardiovascular hospitalizations [39] . A recent observational study also showed a significantly reduced risk for all-cause and cardiovascular mortality among haemodialysis patients treated with cinacalcet [40] . Given that an increased FGF23 is an independent predictor of mortality on haemodialysis [16] , whether the possible survival benefit of cinacalcet is mediated by modulation of FGF23 metabolism is interesting and would be worthy of further investigations.
In the present study, we also showed that pretreatment FGF23 did not predict treatment response to cinacalcet for SHPT, similar to the study by Wetmore et al. [28] . These findings are in contrast to the results of previous studies of active vitamin D therapy [17, 18] . It is noteworthy that such discrepancies in the predictability of FGF23 between the two treatment agents well correspond to the fact that the presence of enlarged parathyroid gland is associated with resistance to active vitamin D therapy [41] [42] [43] but this is not the case for cinacalcet therapy [25] . These data collectively suggest that cinacalcet is effective even in patients with severe SHPT that is or will be resistant to active vitamin D therapy, although we should be aware that there are still some patients who develop progressive SHPT resistant to cinacalcet therapy and need to be referred for surgery [39] .
The strengths of this study include prospective sample acquisition, long follow-up period, uniform data acquisition and the rigorous study protocol for the use of active vitamin D. There are, however, several potential limitations to our study. Firstly, this was a secondary analysis of an open-label single-arm clinical trial that lacked a concurrent control group. These limitations prevented concrete analysis of the effect of cinacalcet on serum FGF23. In addition, this was a per-protocol analysis and we studied only patients who completed the study period and had available serum samples for measuring FGF23, which may have introduced a selection bias in the results. Therefore, our results should be confirmed in future clinical trials with more precise design. We also have no data on changes in dietary phosphorus load during cinacalcet treatment. Because cinacalcet therapy is occasionally associated with gastrointestinal adverse effects [22] [23] [24] [25] , we cannot exclude the possibility that decreased phosphorus load due to the adverse effects may explain the observed reduction in serum FGF23. Finally, in this study, we did not assess the effect of the changes in FGF23 on patient-related outcomes. Whether the decreased FGF23 by cinacalcet provides survival benefits is important and should be investigated in future clinical studies.
In conclusion, in this secondary analysis of the clinical trial, we showed that cinacalcet treatment lowers serum FGF23 levels in haemodialysis patients with SHPT, independently of the effects of active vitamin D. We also found that pretreatment FGF23 is not associated with treatment response to cinacalcet in this setting. The precise mechanism of FGF23 reduction by cinacalcet and its clinical impact on outcomes among haemodialysis patients warrants further investigations.
